Angiotensin II for the Treatment of Vasodilatory Shock.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for the treatment of patients with this condition. METHODS: We randomly assigned patients with vasodilatory shock who were receiving more than 0.2 μg of norepinephrine per kilogram of body weight per minute or the equivalent dose of another vasopressor to receive infusions of either angiotensin II or placebo. The primary end point was a response with respect to mean arterial pressure at hour 3 after the start of infusion, with response defined as an increase from baseline of at least 10 mm Hg or an increase to at least 75 mm Hg, without an increase in the dose of background vasopressors. RESULTS: A total of 344 patients were assigned to one of the two regimens; 321 received a study intervention (163 received angiotensin II, and 158 received placebo) and were included in the analysis. The primary end point was reached by more patients in the angiotensin II group (114 of 163 patients, 69.9%) than in the placebo group (37 of 158 patients, 23.4%) (odds ratio, 7.95; 95% confidence interval [CI], 4.76 to 13.3; P<0.001). At 48 hours, the mean improvement in the cardiovascular Sequential Organ Failure Assessment (SOFA) score (scores range from 0 to 4, with higher scores indicating more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01). Serious adverse events were reported in 60.7% of the patients in the angiotensin II group and in 67.1% in the placebo group. Death by day 28 occurred in 75 of 163 patients (46%) in the angiotensin II group and in 85 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07; P=0.12). CONCLUSIONS: Angiotensin II effectively increased blood pressure in patients with vasodilatory shock that did not respond to high doses of conventional vasopressors. (Funded by La Jolla Pharmaceutical Company; ATHOS-3 number, NCT02338843 .).

Full Text

Duke Authors

Cited Authors

  • Khanna, A; English, SW; Wang, XS; Ham, K; Tumlin, J; Szerlip, H; Busse, LW; Altaweel, L; Albertson, TE; Mackey, C; McCurdy, MT; Boldt, DW; Chock, S; Young, PJ; Krell, K; Wunderink, RG; Ostermann, M; Murugan, R; Gong, MN; Panwar, R; Hästbacka, J; Favory, R; Venkatesh, B; Thompson, BT; Bellomo, R; Jensen, J; Kroll, S; Chawla, LS; Tidmarsh, GF; Deane, AM; ATHOS-3 Investigators,

Published Date

  • August 3, 2017

Published In

Volume / Issue

  • 377 / 5

Start / End Page

  • 419 - 430

PubMed ID

  • 28528561

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1704154


  • eng

Conference Location

  • United States